ES2071131T3 - Di- y tetra-fluor analogos de escualeno como inhibidores de escualeno epoxidasa. - Google Patents

Di- y tetra-fluor analogos de escualeno como inhibidores de escualeno epoxidasa.

Info

Publication number
ES2071131T3
ES2071131T3 ES91101057T ES91101057T ES2071131T3 ES 2071131 T3 ES2071131 T3 ES 2071131T3 ES 91101057 T ES91101057 T ES 91101057T ES 91101057 T ES91101057 T ES 91101057T ES 2071131 T3 ES2071131 T3 ES 2071131T3
Authority
ES
Spain
Prior art keywords
squalene
tetra
fluorine
analogs
epoxidase inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91101057T
Other languages
English (en)
Inventor
Esa T Jarvi
James R Mccarthy
Michael L Edwards
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2071131T3 publication Critical patent/ES2071131T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C21/00—Acyclic unsaturated compounds containing halogen atoms
    • C07C21/02—Acyclic unsaturated compounds containing halogen atoms containing carbon-to-carbon double bonds
    • C07C21/215—Halogenated polyenes with more than two carbon-to-carbon double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Steroid Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)

Abstract

ESTA INVENCION SE REFIERE A CIERTOS NUEVOS ANALOGOS DE DI Y TETRA-FLUOR DE ESCUALENA Y SUS METODOS DE UTILIZACION EN BAJAR EL COLESTEROL DEL PLASMA E INHIBIR LA EXPOSIDASA DE ESCUALENA EN PACIENTES QUE LO NECESITEN.
ES91101057T 1990-03-30 1991-01-28 Di- y tetra-fluor analogos de escualeno como inhibidores de escualeno epoxidasa. Expired - Lifetime ES2071131T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/502,203 US5011859A (en) 1990-03-30 1990-03-30 Di- and tetra-fluoro analogs of squalene as inhibitors of squalene epoxidase

Publications (1)

Publication Number Publication Date
ES2071131T3 true ES2071131T3 (es) 1995-06-16

Family

ID=23996803

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91101057T Expired - Lifetime ES2071131T3 (es) 1990-03-30 1991-01-28 Di- y tetra-fluor analogos de escualeno como inhibidores de escualeno epoxidasa.

Country Status (19)

Country Link
US (1) US5011859A (es)
EP (1) EP0448934B1 (es)
JP (1) JP2911239B2 (es)
KR (1) KR0162659B1 (es)
CN (1) CN1055172A (es)
AT (1) ATE118756T1 (es)
AU (1) AU629726B2 (es)
CA (1) CA2034612C (es)
DE (1) DE69107488T2 (es)
ES (1) ES2071131T3 (es)
FI (1) FI910425A (es)
HU (1) HU208103B (es)
IE (1) IE910181A1 (es)
IL (1) IL97356A0 (es)
NO (1) NO910263L (es)
NZ (1) NZ236800A (es)
PH (1) PH27365A (es)
PT (1) PT96654A (es)
ZA (1) ZA91392B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7238394A (en) * 1993-07-29 1995-02-28 Chugai Seiyaku Kabushiki Kaisha Tricarboxylic acid derivative having squalene synthetase inhibitor activity
DE19754795A1 (de) * 1997-12-10 1999-06-17 Boehringer Ingelheim Pharma Neue Urethane, ihre Thio- und Dithioanaloga, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung
US6103733A (en) * 1998-09-09 2000-08-15 Bachmann; Kenneth A. Method for increasing HDL cholesterol levels using heteroaromatic phenylmethanes
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
CL2007002958A1 (es) * 2006-10-12 2008-05-09 Epix Delaware Inc Compuestos derivados de heteroaril-carboxamida, antagonistas del receptor de quimioquina; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades tales como rechazo de transplante de organos, artritis reumatoidea, lupus, entr
JP5498168B2 (ja) 2006-12-01 2014-05-21 ブリストル−マイヤーズ スクイブ カンパニー アテローム性動脈硬化および循環器疾患の治療のためのｃｅｔｐ阻害剤としてのｎ−（（３−ベンジル）−２，２−（ビス−フェニル）−プロパン−１−アミン誘導体
US20100331298A1 (en) * 2007-12-10 2010-12-30 Cytopathfinder, Inc. Carboxamide Compounds and Their Use
EP2280766A1 (en) 2007-12-11 2011-02-09 CytoPathfinder, Inc. Carboxamide compounds and their use as chemokine receptor agonists
US20130072519A1 (en) 2010-05-21 2013-03-21 Edward Lee Conn 2-phenyl benzoylamides
EP2680874A2 (en) 2011-03-04 2014-01-08 Pfizer Inc Edn3-like peptides and uses thereof
JP2016516804A (ja) 2013-04-17 2016-06-09 ファイザー・インク 心血管疾患を治療するためのｎ−ピペリジン−３−イルベンズアミド誘導体
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
JP7128969B2 (ja) 2019-01-18 2022-08-31 アストラゼネカ・アクチエボラーグ Ｐｃｓｋ９阻害剤及びその使用方法
CN112678833B (zh) * 2020-11-17 2023-08-04 广西中烟工业有限责任公司 纳米二氧化硅改性角鲨烯有机硅颗粒及其制备和使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3876672A (en) * 1972-02-21 1975-04-08 Du Pont Hydroformylation of olefins
DE2913677C2 (de) * 1979-04-05 1983-03-03 Union Rheinische Braunkohlen Kraftstoff AG, 5000 Köln Verfahren zur Herstellung von Acetaldehyddimethylacetal
US4455441A (en) * 1982-09-24 1984-06-19 Research Foundation Of State University Of New York Attractant termiticidal compounds, compositions and methods of use therefor
DE3618115A1 (de) * 1986-05-30 1987-12-03 Bayer Ag Halogenolefine
US4876295A (en) * 1987-03-11 1989-10-24 The Dow Chemical Company Flexible thermoplastic epoxy resin and coatings prepared therefrom

Also Published As

Publication number Publication date
CA2034612C (en) 2001-05-15
PH27365A (en) 1993-06-21
CN1055172A (zh) 1991-10-09
EP0448934B1 (en) 1995-02-22
EP0448934A2 (en) 1991-10-02
FI910425A (fi) 1991-10-01
NZ236800A (en) 1993-05-26
US5011859A (en) 1991-04-30
IL97356A0 (en) 1992-05-25
AU6946891A (en) 1991-10-03
HUT56533A (en) 1991-09-30
NO910263L (no) 1991-10-01
AU629726B2 (en) 1992-10-08
HU208103B (en) 1993-08-30
EP0448934A3 (en) 1991-11-27
DE69107488D1 (de) 1995-03-30
JP2911239B2 (ja) 1999-06-23
JPH04221327A (ja) 1992-08-11
ATE118756T1 (de) 1995-03-15
FI910425A0 (fi) 1991-01-29
KR910016660A (ko) 1991-11-05
KR0162659B1 (ko) 1999-01-15
HU910174D0 (en) 1991-08-28
CA2034612A1 (en) 1991-10-01
PT96654A (pt) 1991-10-31
NO910263D0 (no) 1991-01-23
ZA91392B (en) 1991-10-30
DE69107488T2 (de) 1995-06-14
IE910181A1 (en) 1991-10-09

Similar Documents

Publication Publication Date Title
ES2071131T3 (es) Di- y tetra-fluor analogos de escualeno como inhibidores de escualeno epoxidasa.
ATE178799T1 (de) Methode und zusammensetzungen zur behandlung von zerebralparalyse
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
DE69214610D1 (de) Verfahren zur Behandlung von Erdgas
DE69435321D1 (de) Verwendung von Botulinum Toxin zur Behandlung des myofascialen Schmerzsyndroms
ATE184792T1 (de) 2-bromomelatonin zur behandlung von schlafstörungen
NO307968B1 (no) Pyrazolo- og pyrrolopyridiner og farmasøytisk blanding derav
ATE161013T1 (de) Verfahren zum reinigen von 20 cs)-camptothecin
MX9403380A (es) Inhibidores de proteasa de vih utiles para el tratamiento de sida.
IT1232889B (it) Composizioni e procedimento per il trattamento ammorbidente di tessuti
ES2116594T3 (es) Ansamicinas biciclicas y su uso como agentes antitumorales.
DE68926728D1 (de) Makrolidzusammensetzungen zur Behandlung von Störungen des Bewegungsvermögens des Magendarmtraktes
ATE116848T1 (de) Verwendung von baclofen zur herstellung von arzneimitteln zur behandlung von angina pectoris.
DE69423131D1 (de) Verfahren zur Behandlung von Mycobakterien enthaltenden Auswürfen
NO964238D0 (no) Halofantrin-fri-base for behandling av malaria og blandinger
DE3854121D1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE69429856D1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit
DE69431199D1 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Schlafstörungen
ATE239470T1 (de) Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen
DE69218196D1 (de) Cholesterinsenkende tocopherolanaloga
DE69301936D1 (de) Verfahren zur Behandlung von Rauchgas
ATE114468T1 (de) Ethyl-(+)-apovincaminat zur behandlung der demyelinisierung klinischer erscheinungen autoimmunen ursprungs.
PT68417A (de) Verfahren zur kombinierten mullverwertung und abwasseraufbereitung und mehrstufen-filtrapionsvorrichtungzur durchfuhrung des verfahrens
DK139685A (da) Liposomer med inhalative allergener til behandling af allergier, fremgangsmaade til deres fremstilling og laegemidler indeholdende disseliposomer

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 448934

Country of ref document: ES